Turning pharma castoffs into an instant fortune, Vivek Ramaswamy’s Myovant bags a $218M IPO
In a flashback to the bubbly IPO boom of 2014, Myovant Sciences has rung up $218 million in an overnight windfall after pricing 14.5 million shares at $15 a pop — the high end of the range. Shares will start trading today as the market weighs in on Vivek Ramaswamy’s latest overnight Wall Street coup.
The former hedge fund manager turned an Alzheimer’s reject at GlaxoSmithKline into a $315 million IPO for Axovant $AXON last year, steering the failed therapy straight into a Phase III paid for by his investor fans.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.